HALO — Halozyme Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $4.91bn
- $6.07bn
- $829.25m
- 89
- 39
- 70
- 72
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -72.2 | 129 | 403 | 202 | 282 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 33.3 | 26.8 | 45.4 | 34.3 | 26.3 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -50.5 | -104 | 3.74 | -86 | -38.7 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -85.4 | 55.5 | 299 | 240 | 389 |
Capital Expenditures | -4.04 | -2.5 | -1.46 | -4.81 | -15.3 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -1.51 | 80.9 | -405 | -482 | -81.6 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -5.55 | 78.4 | -406 | -487 | -96.9 |
Financing Cash Flow Items | -0.279 | 0 | -0.424 | -76.2 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 153 | -106 | 77.9 | 362 | -408 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 62.2 | 27.5 | -29 | 115 | -116 |